Interest is growing in schemes that involve “paying for pills by results” (Pollock, 2007), i.e. “paying for performance” rather than merely “paying for pills”. Hard-pressed health care payers want to know that they are getting what they are paying for health interventions and other...

Most European Member States, particularly the former EU15 countries, have national systems providing universal access to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare, national governments have introduced mechanisms to regulate...

Objective: The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments, with particular focus on the methods for constructing QALYs preferred by NICE. Methods: Data were obtained using a keyword search of the MEDLINE database and a hand...

Objectives: This research was intended to explore whether wealth effects of drug interventions, including productivity gains and savings in other sectors, are considered in resource allocations by health technology assessment (HTA) agencies and government departments. It also analyses reasons...

The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments, with particular focus on the methods for constructing QALYs preferred by the UK National Institute for Health and Clinical Excellence (NICE). Data were obtained using a keyword...

Rational: The most significant initiative to address the innovation gap for neglected diseases affecting poor populations in poor countries has been the establishment of Public-Private Partnerships for product development (PD PPPs) which have been supported in conception and funding by a number...

The results highlight a societal view that the severity of chemotherapy- related anaemia will significantly affect cancer patients’ HR-QOL. The DCE survey shows that the public value favourably the attributes of treatment with recombinant erythropoietin, and indicates a likely patient...

Bariatric surgery produced additional life expectancy (80–81 years) compared to no surgery (78 years). The incremental cost-effectiveness ratios (ICERs) of the surgical procedures were US $6,600 per quality-adjusted life expectancy (QALY) gained for LRYGB, US $6,200 for LAGB, and...